FDA Extends Review Timeline for Denali Therapeutics’ Tividenofusp Alfa in Hunter Syndrome

Denali Therapeutics (Nasdaq: DNLI) announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its Biologics License Application (BLA) for tividenofusp alfa, an investigational therapy…

Continue Reading FDA Extends Review Timeline for Denali Therapeutics’ Tividenofusp Alfa in Hunter Syndrome